2025 European Society for Medical Oncology (ESMO)

Posted by smoore4 @smoore4, 1 day ago

This is more of an FYI. Below is an article, and video, with some interesting results, particularly ADT + ARPI and potential for adding Lutetium (Pluvicto) as well (aka PSMAddition). Worth a look for high-risk patients.
https://www.pcf.org/esmo-2025-highlights
Steve

Summary....

* New data on hormone therapy options for men with high-risk localized disease—including who can safely stay on standard therapy and who may benefit from more intensive treatment alongside radiation.

* Treatment options for recurrent prostate cancer with a fast PSA doubling time—adding enzalutamide to standard hormone therapy reduced the risk of death by 40% in one study, while adding apalutamide to hormone therapy delayed treatment resistance.

* A new medicine for patients with specific gene changes—capivasertib delayed progression on scans when combined with abiraterone.

* Expanding use of lutetium–PSMA-617—currently used mainly in metastatic castration-resistant prostate cancer, this treatment showed benefit when given earlier to men with metastatic hormone-sensitive disease.

* The latest recommendations on genetic testing—both germline (inherited) and somatic (tumor) tests, plus a new PCF resource to help you understand these tests and talk to your doctor.

Interested in more discussions like this? Go to the Prostate Cancer Support Group.

smoore4 | @smoore4 | 1 day ago

Lutetium–PSMA-617 is Pluvicto.

heavyphil | @heavyphil | 1 day ago

In reply to @smoore4 "Lutetium–PSMA-617 is Pluvicto." + (show)

@smoore4 You know, the more you think about it, it makes so much sense! Here is a drug that can SELECTIVELY kill PCa cells - not every cell in its path.
Dollars to donuts, in a few years they’ll be doing this more instead of present SRT regimens. Good find…
Phil

smoore4 | @smoore4 | 1 day ago

In reply to @heavyphil "@smoore4 You know, the more you think about it, it makes so much sense! Here is..." + (show)

@heavyphil I agree 100% Phil! There are side effects of course, but the science of locking on to known prostate cancer cells, leaving the healthy ones alone, is amazing. We all know that is what a PSMA PET scan does anyway, so why not add a kill switch for the cell. Can definitely see this becoming a standard of care.